Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP), a Delaware corporation headquartered in Bothell, WA, filed this Current Report on Form 8-K on January 13, 2025. The filing serves as a Regulation FD disclosure regarding a corporate presentation made to the investment community on the same date.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to disclose the existence of a presentation rather than a financial results report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document solely announces the delivery of a corporate presentation.
Guidance, Outlook, and Risks
The Company furnished a slide presentation (Exhibit 99.1) to the investment community. The filing explicitly states that the information contained in this Item 7.01 and the accompanying presentation is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into other filings. Consequently, specific guidance, outlook, or risk factors are not detailed within the text of this 8-K.
Key Facts for Investor Verification
- Verify the content of the corporate presentation by reviewing Exhibit 99.1 attached to the full filing.
- Note that the presentation materials are not legally "filed" and do not carry the same liability protections as standard SEC filings.
- Confirm the Company's status as an emerging growth company (indicated as unchecked in the form header).
- Review the Company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains none.